IRIS Research and Development, LLC
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA) as a therapeutic, or is recommended (e.g., in Systemic Lupus Erythematosus (SLE) as a cornerstone for disease management.
Rheumatoid Arthritis
Pemphigus Vulgaris
Granulomatosis With Polyangiitis
Systemic Lupus Erythematosus
AB-101
Rituximab
Cyclophosphamide
Fludarabine
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 30 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. |
Actual Study Start Date : | 2024-05-15 |
Estimated Primary Completion Date : | 2027-07 |
Estimated Study Completion Date : | 2028-12 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
IRIS Research and Development, LLC
Plantation, Florida, United States, 33324